Study defines distinct sympathoneural and cardiovagal baroreflex domains in autonomic synucleinopathies

A retrospective study reports that indices derived from the Valsalva maneuver capture distinct sympathoneural and cardiovagal domains of arterial baroreflex function, enabling efficient autonomic assessment in patients with synucleinopathies.

A retrospective observational study published in Clinical Autonomic Research analyzed physiological and neurochemical biomarkers of arterial baroreflex function in patients with autonomic synucleinopathies.

The study cohort consisted of 38 patients with pure autonomic failure (PAF), 63 with Parkinson's disease with orthostatic hypotension (PD + OH), 63 with Parkinson's disease without orthostatic hypotension (PD No OH), 72 with multiple system atrophy (MSA), and 130 controls.

Investigators compared 10 baroreflex-sympathoneural and 6 baroreflex-cardiovagal indices, finding that measures within each domain were strongly correlated, but correlation between the two domains was weak.

Among sympathoneural measures, pressure recovery time after the Valsalva maneuver, the logarithm of the total baroreflex area, and the fractional orthostatic increment in plasma norepinephrine best distinguished patients from controls.

Among cardiovagal measures, the Phase II Valsalva Baroslope and logarithms of low- and high-frequency heart rate variability during supine rest were the most informative.

No baroreflex measure successfully differentiated pure autonomic failure from Parkinson's disease with orthostatic hypotension or multiple system atrophy.

The findings demonstrate that the arterial baroreflex has distinct, weakly correlated sympathoneural and cardiovagal efferent limbs, rather than serving as interchangeable indicators of a single physiological construct.

The results suggest that non-invasive measurements of blood pressure and interbeat interval responses during the Valsalva maneuver capture most of the clinically meaningful variation, streamlining autonomic assessment.

The inability of baroreflex measures to distinguish between PAF, PD + OH, and MSA highlights the overlapping pathophysiological profiles of autonomic impairment in these synucleinopathies.

Standardizing accessible physiological markers like the Valsalva Baroslope and pressure recovery time could refine patient stratification in clinical trials for therapies targeting synucleinpathies.

Developers of neurodegenerative therapies may use these physiological parameters to monitor autonomic safety or potential systemic efficacy in clinical study cohorts.

Prospective validation of these specific baroreflex indices to determine their clinical utility as progressional biomarkers in therapeutic trials.